Symbols / BMRA $2.17 -0.91% Biomerica, Inc.
BMRA Chart
About
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 6.55M |
| Enterprise Value | 4.29M | Income | -4.03M | Sales | 4.46M |
| Book/sh | 1.50 | Cash/sh | 0.84 | Dividend Yield | — |
| Payout | 0.00% | Employees | 53 | IPO | — |
| P/E | — | Forward P/E | 5.56 | PEG | — |
| P/S | 1.47 | P/B | 1.44 | P/C | — |
| EV/EBITDA | -0.83 | EV/Sales | 0.96 | Quick Ratio | 2.18 |
| Current Ratio | 3.25 | Debt/Eq | 6.40 | LT Debt/Eq | — |
| EPS (ttm) | -2.51 | EPS next Y | 0.39 | EPS Growth | — |
| Revenue Growth | -26.00% | Earnings | 2023-04-14 16:00 | ROA | -49.44% |
| ROE | -84.30% | ROIC | — | Gross Margin | 5.63% |
| Oper. Margin | -113.47% | Profit Margin | -90.31% | Shs Outstand | 3.02M |
| Shs Float | 2.70M | Short Float | 1.69% | Short Ratio | 1.93 |
| Short Interest | — | 52W High | 4.88 | 52W Low | 1.87 |
| Beta | 0.20 | Avg Volume | 22.07K | Volume | 14.78K |
| Target Price | — | Recom | None | Prev Close | $2.19 |
| Price | $2.17 | Change | -0.91% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2020-10-19 | main | Aegis Capital | — → Buy | $11 |
| 2020-09-04 | main | Aegis Capital | — → Buy | $13 |
| 2020-08-21 | init | Aegis Capital | — → Buy | $10 |
| 2018-12-17 | main | B. Riley Securities | Buy → Buy | $6 |
- New finger-stick IBS test eases pain and bloating for most patients - stocktitan.net hu, 26 Feb 2026 08
- BMRA: Biomerica - Interactive Chart - Zacks Investment Research hu, 02 Apr 2026 19
- Biomerica Secures First Commercial Order for Hp Detect™ from Major European Laboratory Chain - quiverquant.com Wed, 18 Mar 2026 07
- symbol__ Stock Quote Price and Forecast - CNN Sun, 31 Mar 2024 09
- Stomach cancer bacteria drives major lab’s first order of Hp Detect test - stocktitan.net Wed, 18 Mar 2026 07
- Biomerica’s Market Presence Expands with Egyptian Drug Authority Authorization - timothysykes.com ue, 23 Dec 2025 08
- Biomerica Stock Price Forecast. Should You Buy BMRA? - StockInvest.us ue, 01 Dec 2020 11
- BMRA Stock Price and Chart — NASDAQ:BMRA - TradingView Mon, 31 Jul 2017 07
- New UK lab test targets H. pylori, a bacterial infection in 44% of people - stocktitan.net hu, 05 Mar 2026 08
- Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans? - finance.yahoo.com Wed, 20 Dec 2023 08
- BMRA Stock Price, Quote & Chart | BIOMERICA INC (NASDAQ:BMRA) - ChartMill Wed, 12 Feb 2020 19
- Biomedical Stock Biomerica Inc. (NASDAQ: BMRA) Makes NASDAQ TOP Gainer List on UAE Ministry of Health and Prevention Approval - Investorideas.com hu, 16 Jan 2025 08
- Biomerica, Inc. (BMRA) stock price, news, quote and history - Yahoo Finance Australia Wed, 14 Jun 2017 08
- Biomerica (BMRA) - Zacks Investment Research Sat, 23 Apr 2016 05
- Biomerica, Inc. Reports 4% Decline in Operating Expenses Year-to-Date and Strengthens Balance Sheet with 14.7% Improvement in Working Capital - quiverquant.com Wed, 14 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
5.31
-1.92%
|
5.42
+1.42%
|
5.34
-71.71%
|
18.87
|
| Operating Revenue |
|
5.31
-1.92%
|
5.42
+1.42%
|
5.34
-71.71%
|
18.87
|
| Cost Of Revenue |
|
4.81
+0.19%
|
4.80
-1.82%
|
4.89
-69.21%
|
15.89
|
| Reconciled Cost Of Revenue |
|
4.81
+0.19%
|
4.80
-1.82%
|
4.89
-69.21%
|
15.89
|
| Gross Profit |
|
0.50
-18.49%
|
0.61
+37.00%
|
0.45
-85.02%
|
2.98
|
| Operating Expense |
|
5.63
-19.25%
|
6.98
-9.01%
|
7.67
+2.10%
|
7.51
|
| Research And Development |
|
1.02
-31.39%
|
1.49
-5.87%
|
1.58
-12.58%
|
1.81
|
| Selling General And Administration |
|
4.61
-15.95%
|
5.49
-9.83%
|
6.08
+6.77%
|
5.70
|
| Total Expenses |
|
10.45
-11.32%
|
11.78
-6.21%
|
12.56
-46.33%
|
23.41
|
| Operating Income |
|
-5.14
+19.32%
|
-6.37
+11.85%
|
-7.22
-59.31%
|
-4.53
|
| Total Operating Income As Reported |
|
-5.14
+19.32%
|
-6.37
+11.85%
|
-7.22
-59.31%
|
-4.53
|
| EBITDA |
|
-4.74
+20.96%
|
-5.99
+12.79%
|
-6.87
-74.46%
|
-3.94
|
| Normalized EBITDA |
|
-4.74
+20.96%
|
-5.99
+12.79%
|
-6.87
-74.46%
|
-3.94
|
| Reconciled Depreciation |
|
0.40
+6.95%
|
0.37
+6.55%
|
0.35
-41.01%
|
0.59
|
| EBIT |
|
-5.14
+19.32%
|
-6.37
+11.85%
|
-7.22
-59.31%
|
-4.53
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Pretax Income |
|
-4.97
+16.24%
|
-5.94
+16.26%
|
-7.09
-57.29%
|
-4.51
|
| Net Non Operating Interest Income Expense |
|
0.17
-61.72%
|
0.43
+224.06%
|
0.13
+392.59%
|
0.03
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
0.17
-61.72%
|
0.43
+224.06%
|
0.13
+392.59%
|
0.03
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
0.17
-61.72%
|
0.43
+224.06%
|
0.13
+392.59%
|
0.03
|
| Interest Income |
|
0.17
-61.72%
|
0.43
+224.06%
|
0.13
+392.59%
|
0.03
|
| Other Income Expense |
|
—
|
—
|
0.00
|
—
|
| Other Non Operating Income Expenses |
|
—
|
—
|
0.00
|
—
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
0.00
-97.62%
|
0.04
-17.65%
|
0.05
+112.50%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Net Income From Continuing Operation Net Minority Interest |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Net Income From Continuing And Discontinued Operation |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Net Income Continuous Operations |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Normalized Income |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Net Income Common Stockholders |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Diluted EPS |
|
-2.16
+23.94%
|
-2.84
+29.00%
|
-4.00
-38.89%
|
-2.88
|
| Basic EPS |
|
-2.16
+23.94%
|
-2.84
+29.00%
|
-4.00
-38.89%
|
-2.88
|
| Basic Average Shares |
|
2.30
+9.22%
|
2.10
+18.87%
|
1.77
+11.69%
|
1.58
|
| Diluted Average Shares |
|
2.30
+9.22%
|
2.10
+18.87%
|
1.77
+11.69%
|
1.58
|
| Diluted NI Availto Com Stockholders |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Line Item | Trend | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Total Assets |
|
5.95
-35.76%
|
9.25
-35.98%
|
14.45
+27.08%
|
11.37
|
| Current Assets |
|
4.88
-36.94%
|
7.73
-39.59%
|
12.80
+35.75%
|
9.43
|
| Cash Cash Equivalents And Short Term Investments |
|
2.40
-42.47%
|
4.17
-57.09%
|
9.72
+64.26%
|
5.92
|
| Cash And Cash Equivalents |
|
2.40
-42.47%
|
4.17
-57.09%
|
9.72
+64.26%
|
5.92
|
| Receivables |
|
0.73
-22.81%
|
0.95
+31.16%
|
0.72
-6.72%
|
0.77
|
| Accounts Receivable |
|
0.73
-22.81%
|
0.95
+31.16%
|
0.72
-6.72%
|
0.77
|
| Gross Accounts Receivable |
|
0.76
-21.64%
|
0.97
+28.63%
|
0.75
-18.99%
|
0.93
|
| Allowance For Doubtful Accounts Receivable |
|
-0.03
-36.84%
|
-0.02
+34.48%
|
-0.03
+81.05%
|
-0.15
|
| Inventory |
|
1.49
-37.29%
|
2.38
+15.56%
|
2.06
-14.90%
|
2.42
|
| Raw Materials |
|
1.07
-29.49%
|
1.52
-9.42%
|
1.68
-2.33%
|
1.72
|
| Work In Process |
|
0.74
-35.11%
|
1.15
+31.76%
|
0.87
+13.89%
|
0.76
|
| Finished Goods |
|
0.15
-17.88%
|
0.18
-1.65%
|
0.18
-76.73%
|
0.78
|
| Prepaid Assets |
|
—
|
0.24
-20.67%
|
0.30
-6.33%
|
0.32
|
| Other Current Assets |
|
0.26
+7.14%
|
0.24
-20.67%
|
0.30
-6.25%
|
0.32
|
| Total Non Current Assets |
|
1.07
-29.74%
|
1.52
-8.09%
|
1.66
-14.89%
|
1.95
|
| Net PPE |
|
0.56
-40.19%
|
0.94
-24.44%
|
1.25
-17.68%
|
1.52
|
| Gross PPE |
|
3.25
+0.00%
|
3.25
+1.60%
|
3.20
-9.87%
|
3.55
|
| Accumulated Depreciation |
|
-2.68
-16.45%
|
-2.30
-18.28%
|
-1.95
+4.04%
|
-2.03
|
| Machinery Furniture Equipment |
|
0.21
+0.00%
|
0.21
+0.00%
|
0.21
-7.05%
|
0.23
|
| Other Properties |
|
3.04
+0.00%
|
3.04
+1.71%
|
2.98
-10.06%
|
3.32
|
| Goodwill And Other Intangible Assets |
|
0.23
+7.55%
|
0.21
+28.48%
|
0.17
-2.94%
|
0.17
|
| Other Intangible Assets |
|
0.23
+7.55%
|
0.21
+28.48%
|
0.17
-2.94%
|
0.17
|
| Investments And Advances |
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
|
| Other Non Current Assets |
|
0.11
-44.33%
|
0.20
+156.96%
|
0.08
-17.71%
|
0.10
|
| Total Liabilities Net Minority Interest |
|
1.84
-30.90%
|
2.66
-2.45%
|
2.73
-10.46%
|
3.05
|
| Current Liabilities |
|
1.74
-21.05%
|
2.20
+13.32%
|
1.95
-3.28%
|
2.01
|
| Payables And Accrued Expenses |
|
0.67
-40.95%
|
1.14
+27.58%
|
0.89
-8.23%
|
0.97
|
| Payables |
|
0.29
-47.32%
|
0.56
+62.79%
|
0.34
-53.26%
|
0.74
|
| Accounts Payable |
|
0.29
-47.32%
|
0.56
+62.79%
|
0.34
-53.26%
|
0.74
|
| Current Accrued Expenses |
|
0.38
-34.78%
|
0.58
+5.47%
|
0.55
+132.20%
|
0.24
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.66
+0.00%
|
0.66
-5.89%
|
0.70
+7.57%
|
0.65
|
| Current Debt And Capital Lease Obligation |
|
0.36
+9.82%
|
0.33
+9.76%
|
0.30
-12.90%
|
0.34
|
| Current Capital Lease Obligation |
|
0.36
+9.82%
|
0.33
+9.76%
|
0.30
-12.90%
|
0.34
|
| Current Deferred Liabilities |
|
0.06
-35.29%
|
0.09
+41.67%
|
0.06
+17.65%
|
0.05
|
| Current Deferred Revenue |
|
0.06
-35.29%
|
0.09
+41.67%
|
0.06
+17.65%
|
0.05
|
| Other Current Liabilities |
|
—
|
—
|
—
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.10
-78.21%
|
0.46
-41.53%
|
0.79
-24.37%
|
1.04
|
| Long Term Debt And Capital Lease Obligation |
|
0.10
-78.21%
|
0.46
-41.53%
|
0.79
-24.37%
|
1.04
|
| Long Term Capital Lease Obligation |
|
0.10
-78.21%
|
0.46
-41.53%
|
0.79
-24.37%
|
1.04
|
| Stockholders Equity |
|
4.11
-37.72%
|
6.59
-43.78%
|
11.72
+40.83%
|
8.32
|
| Common Stock Equity |
|
4.11
-37.72%
|
6.59
-43.78%
|
11.72
+40.83%
|
8.32
|
| Capital Stock |
|
0.20
+20.83%
|
0.17
-87.52%
|
1.35
+30.81%
|
1.03
|
| Common Stock |
|
0.20
+20.83%
|
0.17
-87.52%
|
1.35
+30.81%
|
1.03
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
2.55
+21.09%
|
2.10
+0.00%
|
2.10
+30.73%
|
1.61
|
| Ordinary Shares Number |
|
2.55
+21.09%
|
2.10
+0.00%
|
2.10
+30.73%
|
1.61
|
| Additional Paid In Capital |
|
57.17
+4.49%
|
54.72
+3.82%
|
52.70
+24.17%
|
42.45
|
| Retained Earnings |
|
-53.17
-10.32%
|
-48.20
-14.16%
|
-42.22
-20.36%
|
-35.08
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.10
-2.94%
|
-0.10
+7.27%
|
-0.11
-48.65%
|
-0.07
|
| Other Equity Adjustments |
|
-0.10
-2.94%
|
-0.10
+7.27%
|
-0.11
-48.65%
|
-0.07
|
| Total Equity Gross Minority Interest |
|
4.11
-37.72%
|
6.59
-43.78%
|
11.72
+40.83%
|
8.32
|
| Total Capitalization |
|
4.11
-37.72%
|
6.59
-43.78%
|
11.72
+40.83%
|
8.32
|
| Working Capital |
|
3.13
-43.28%
|
5.53
-49.07%
|
10.85
+46.33%
|
7.42
|
| Invested Capital |
|
4.11
-37.72%
|
6.59
-43.78%
|
11.72
+40.83%
|
8.32
|
| Total Debt |
|
0.46
-41.66%
|
0.79
-27.45%
|
1.08
-21.54%
|
1.38
|
| Capital Lease Obligations |
|
0.46
-41.66%
|
0.79
-27.45%
|
1.08
-21.54%
|
1.38
|
| Net Tangible Assets |
|
3.88
-39.22%
|
6.38
-44.81%
|
11.56
+41.74%
|
8.15
|
| Tangible Book Value |
|
3.88
-39.22%
|
6.38
-44.81%
|
11.56
+41.74%
|
8.15
|
| Inventories Adjustments Allowances |
|
-0.47
-0.86%
|
-0.47
+30.51%
|
-0.67
+20.57%
|
-0.85
|
| Investmentin Financial Assets |
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
|
| Line Item | Trend | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.84
+28.35%
|
-5.36
+2.06%
|
-5.47
-1042.80%
|
-0.48
|
| Cash Flow From Continuing Operating Activities |
|
-3.84
+28.35%
|
-5.36
+2.06%
|
-5.47
-1042.80%
|
-0.48
|
| Net Income From Continuing Operations |
|
-4.97
+16.81%
|
-5.98
+16.27%
|
-7.14
-57.58%
|
-4.53
|
| Depreciation Amortization Depletion |
|
0.40
+6.95%
|
0.37
+6.55%
|
0.35
-41.01%
|
0.59
|
| Depreciation |
|
0.40
+6.95%
|
0.37
+6.55%
|
0.35
-41.01%
|
0.59
|
| Depreciation And Amortization |
|
0.40
+6.95%
|
0.37
+6.55%
|
0.35
-41.01%
|
0.59
|
| Stock Based Compensation |
|
0.46
-45.04%
|
0.84
-29.37%
|
1.19
-5.95%
|
1.26
|
| Provisionand Write Offof Assets |
|
0.00
+101.95%
|
-0.20
-17.82%
|
-0.17
+88.05%
|
-1.46
|
| Operating Gains Losses |
|
—
|
—
|
—
|
0.05
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.05
|
| Change In Working Capital |
|
0.27
+168.89%
|
-0.39
-227.96%
|
0.30
-91.56%
|
3.60
|
| Change In Receivables |
|
0.21
+197.21%
|
-0.21
+26.12%
|
-0.29
-121.32%
|
1.36
|
| Changes In Account Receivables |
|
0.21
+197.21%
|
-0.21
+26.12%
|
-0.29
-121.32%
|
1.36
|
| Change In Inventory |
|
0.88
+866.96%
|
-0.12
-121.54%
|
0.53
-65.81%
|
1.56
|
| Change In Prepaid Assets |
|
-0.02
-127.42%
|
0.06
+210.00%
|
0.02
-60.00%
|
0.05
|
| Change In Payables And Accrued Expense |
|
-0.47
-326.83%
|
0.20
+761.29%
|
-0.03
-104.79%
|
0.65
|
| Change In Accrued Expense |
|
0.00
+102.44%
|
-0.04
-183.67%
|
0.05
-81.01%
|
0.26
|
| Change In Payable |
|
-0.47
-289.43%
|
0.25
+407.50%
|
-0.08
-120.57%
|
0.39
|
| Change In Account Payable |
|
-0.47
-289.43%
|
0.25
+407.50%
|
-0.08
-120.57%
|
0.39
|
| Change In Other Working Capital |
|
-0.02
-246.67%
|
0.01
-95.73%
|
0.35
+588.24%
|
0.05
|
| Change In Other Current Assets |
|
0.01
+118.18%
|
-0.04
-344.44%
|
0.02
-89.35%
|
0.17
|
| Change In Other Current Liabilities |
|
-0.33
-10.10%
|
-0.30
+0.00%
|
-0.30
-21.72%
|
-0.24
|
| Investing Cash Flow |
|
-0.04
+67.83%
|
-0.12
-47.44%
|
-0.08
+54.12%
|
-0.17
|
| Cash Flow From Continuing Investing Activities |
|
-0.04
+67.83%
|
-0.12
-47.44%
|
-0.08
+54.12%
|
-0.17
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.05
+20.31%
|
-0.06
-12.28%
|
-0.06
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.05
+20.31%
|
-0.06
-12.28%
|
-0.06
|
| Capital Expenditure |
|
-0.04
+67.83%
|
-0.12
-47.44%
|
-0.08
+54.12%
|
-0.17
|
| Capital Expenditure Reported |
|
-0.04
+42.19%
|
-0.06
-357.14%
|
-0.01
|
—
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
-0.01
+87.61%
|
-0.11
|
| Purchase Of Intangibles |
|
—
|
—
|
-0.01
+87.61%
|
-0.11
|
| Financing Cash Flow |
|
2.11
+2706.17%
|
-0.08
-100.86%
|
9.39
+292.23%
|
2.39
|
| Cash Flow From Continuing Financing Activities |
|
2.11
+2706.17%
|
-0.08
-100.86%
|
9.39
+292.23%
|
2.39
|
| Net Common Stock Issuance |
|
2.14
|
0.00
-100.00%
|
10.01
+316.90%
|
2.40
|
| Common Stock Payments |
|
—
|
0.00
+100.00%
|
-0.70
-729.41%
|
-0.09
|
| Repurchase Of Capital Stock |
|
—
|
0.00
+100.00%
|
-0.70
-729.41%
|
-0.09
|
| Proceeds From Stock Option Exercised |
|
0.01
|
0.00
-100.00%
|
0.08
+5.19%
|
0.08
|
| Net Other Financing Charges |
|
-0.05
+41.98%
|
-0.08
+88.51%
|
-0.70
-729.41%
|
-0.09
|
| Changes In Cash |
|
-1.77
+68.20%
|
-5.56
-244.79%
|
3.84
+120.07%
|
1.74
|
| Effect Of Exchange Rate Changes |
|
-0.00
-137.50%
|
0.01
+122.22%
|
-0.04
-38.46%
|
-0.03
|
| Beginning Cash Position |
|
4.17
-57.09%
|
9.72
+64.26%
|
5.92
+40.91%
|
4.20
|
| End Cash Position |
|
2.40
-42.45%
|
4.17
-57.09%
|
9.72
+64.26%
|
5.92
|
| Free Cash Flow |
|
-3.88
+29.18%
|
-5.48
+1.37%
|
-5.55
-755.47%
|
-0.65
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
0.01
-75.61%
|
0.04
-19.61%
|
0.05
+112.50%
|
0.02
|
| Common Stock Issuance |
|
2.14
|
0.00
-100.00%
|
10.01
+316.90%
|
2.40
|
| Issuance Of Capital Stock |
|
2.14
|
0.00
-100.00%
|
10.01
+316.90%
|
2.40
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-01-28 View
- 10-Q2026-01-14 View
- 42025-12-31 View
- 42025-12-31 View
- 42025-12-31 View
- 42025-12-31 View
- 42025-12-31 View
- 8-K2025-12-16 View
- 10-Q2025-10-14 View
- 8-K2025-10-08 View
- 10-K2025-08-29 View
- 8-K2025-06-06 View
- 8-K2025-04-16 View
- 10-Q2025-04-14 View
- 10-Q2025-01-14 View
- 42024-12-17 View
- 42024-12-17 View
- 42024-12-17 View
- 42024-12-17 View
- 42024-12-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|